麗珠醫藥(01513.HK)聯合申報注射劑開展三期臨床試驗
麗珠醫藥(01513.HK)公布,控股附屬公司麗珠單抗與北京鑫康合生物醫藥科技聯合申報的重組抗人IL-17A/F人源化單克隆抗體注射液已完成二期臨床試驗,並於近日開展三期臨床試驗。
該注射劑已完成二期臨床試驗期中分析,研究結果顯示整體安全性良好,常見不良事件發生率與同靶點藥物類似,且具有起效快及療效維持時間長等特點。此次擬開展的是一項多中心、隨機、雙盲、陽性對照三期臨床試驗,旨在評估對比司庫奇尤單抗(商品名為可善挺)治療中度至重度慢性斑塊狀銀屑病的有效性和安全性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.